FDA approval of crovalimab: a milestone in paroxysmal nocturnal hemoglobinuria treatment.
作者信息
Anwar Diya, Khan Asim Ali, Ahmed Hooriya, Rashmeen Syeda, Farhat Solay, Shahnoor Syeda, Khan Abdul Moiz
机构信息
Department of Internal Medicine, Ayub Medical College, Abbottabad, Pakistan.
Department of Internal Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
出版信息
Ann Med Surg (Lond). 2025 Jan 9;87(1):27-29. doi: 10.1097/MS9.0000000000002848. eCollection 2025 Jan.
Abstract
摘要
相似文献
1
FDA approval of crovalimab: a milestone in paroxysmal nocturnal hemoglobinuria treatment.美国食品药品监督管理局批准克罗瓦利单抗：阵发性夜间血红蛋白尿治疗的一个里程碑。
Ann Med Surg (Lond). 2025 Jan 9;87(1):27-29. doi: 10.1097/MS9.0000000000002848. eCollection 2025 Jan.
2
Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape.阵发性睡眠性血红蛋白尿治疗领域中的克罗瓦利单抗
Immunotherapy. 2024;16(20-22):1185-1196. doi: 10.1080/1750743X.2024.2433410. Epub 2024 Dec 2.
3
Crovalimab: a new era in paroxysmal nocturnal hemoglobinuria management.克罗伐利单抗：阵发性夜间血红蛋白尿治疗的新时代。
Ann Med Surg (Lond). 2025 Jan 30;87(2):451-453. doi: 10.1097/MS9.0000000000002775. eCollection 2025 Feb.
4
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.第 3 阶段随机化 COMMODORE 1 试验：在补体抑制剂经治的阵发性睡眠性血红蛋白尿症患者中，crovalimab 对比依库珠单抗。
Am J Hematol. 2024 Sep;99(9):1757-1767. doi: 10.1002/ajh.27413. Epub 2024 Jun 25.
5
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.三期随机 COMMODORE 2 试验：初治补体抑制的阵发性睡眠性血红蛋白尿症患者中 Crovalimab 与依库珠单抗的比较。
Am J Hematol. 2024 Sep;99(9):1768-1777. doi: 10.1002/ajh.27412. Epub 2024 Jun 17.
6
Crovalimab: First Approval.克罗伐利单抗：首次批准。
Drugs. 2024 Jun;84(6):707-716. doi: 10.1007/s40265-024-02032-5. Epub 2024 May 14.
7
Mitigating Drug-Target-Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors.阵发性夜间血红蛋白尿症患者更换C5抑制剂时减轻药物-靶点-药物复合物的情况
Clin Pharmacol Ther. 2023 Apr;113(4):904-915. doi: 10.1002/cpt.2851. Epub 2023 Feb 12.
8
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.补体 C5 抑制剂 crovalimab 治疗阵发性睡眠性血红蛋白尿症。
Blood. 2020 Mar 19;135(12):912-920. doi: 10.1182/blood.2019003399.
9
Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trial.阵发性睡眠性血红蛋白尿症患者的克罗伐利单抗治疗：I/II 期 COMPOSER 试验的长期结果。
Eur J Haematol. 2023 Aug;111(2):300-310. doi: 10.1111/ejh.14011. Epub 2023 Jun 15.
10
Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH): Pooled Results From the Phase 3 COMMODORE Studies.阵发性睡眠性血红蛋白尿（PNH）患者中克罗伐利单抗与依库珠单抗的安全性：3期COMMODORE研究的汇总结果。
Eur J Haematol. 2025 Feb;114(2):373-382. doi: 10.1111/ejh.14339. Epub 2024 Nov 13.
本文引用的文献
1
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.第 3 阶段随机化 COMMODORE 1 试验：在补体抑制剂经治的阵发性睡眠性血红蛋白尿症患者中，crovalimab 对比依库珠单抗。
Am J Hematol. 2024 Sep;99(9):1757-1767. doi: 10.1002/ajh.27413. Epub 2024 Jun 25.
2
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.三期随机 COMMODORE 2 试验：初治补体抑制的阵发性睡眠性血红蛋白尿症患者中 Crovalimab 与依库珠单抗的比较。
Am J Hematol. 2024 Sep;99(9):1768-1777. doi: 10.1002/ajh.27412. Epub 2024 Jun 17.
3
Crovalimab: First Approval.克罗伐利单抗：首次批准。
Drugs. 2024 Jun;84(6):707-716. doi: 10.1007/s40265-024-02032-5. Epub 2024 May 14.
4
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study.C5 抑制剂 crovalimab 在补体抑制剂初治的 PNH 患者中的疗效和安全性（COMMODORE 3）：一项多中心、3 期、单臂研究。
Am J Hematol. 2023 Sep;98(9):1407-1414. doi: 10.1002/ajh.26998. Epub 2023 Jul 8.
5
Relationship of paroxysmal nocturnal hemoglobinuria (PNH) granulocyte clone size to disease burden and risk of major vascular events in untreated patients: results from the International PNH Registry.阵发性睡眠性血红蛋白尿症（PNH）粒细胞克隆大小与未治疗患者疾病负担和主要血管事件风险的关系：来自国际 PNH 登记处的结果。
Ann Hematol. 2023 Jul;102(7):1637-1644. doi: 10.1007/s00277-023-05269-4. Epub 2023 May 18.
6
The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey.阵发性睡眠性血红蛋白尿症患者接受 C5 抑制剂依库珠单抗或拉维珠单抗治疗的疾病负担：来自美国患者调查的结果。
Ann Hematol. 2022 Feb;101(2):251-263. doi: 10.1007/s00277-021-04715-5. Epub 2022 Jan 1.
7
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.补体 C5 抑制剂 crovalimab 治疗阵发性睡眠性血红蛋白尿症。
Blood. 2020 Mar 19;135(12):912-920. doi: 10.1182/blood.2019003399.
8
Complement-mediated haemolysis and the role of blood transfusion in paroxysmal nocturnal haemoglobinuria.补体介导的溶血及输血在阵发性夜间血红蛋白尿中的作用。
Blood Transfus. 2015 Jul;13(3):363-9. doi: 10.2450/2015.0249-14. Epub 2015 Feb 2.
9
Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents.阵发性夜间血红蛋白尿：生物制剂时代的病理生理学、自然病史及治疗选择
Biologics. 2008 Jun;2(2):205-22. doi: 10.2147/btt.s1420.
Zotero 插件